Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

Autor: Armstrong AW; Keck School of Medicine of University of Southern California, Los Angeles, CA, USA., Augustin M; Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Beaumont JL; Clinical Outcomes Solutions, Tucson, AZ, USA., Pham TP; Clinical Outcomes Solutions, Tucson, AZ, USA., Hudgens S; Clinical Outcomes Solutions, Tucson, AZ, USA., Gordon KB; Medical College of Wisconsin, Milwaukee, WI, USA., Zhuo J; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA. joe.zhuo@bms.com., Becker B; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA., Zhong Y; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA., Kisa RM; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA., Banerjee S; Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA., Papp KA; Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada.; University of Toronto, Toronto, ON, Canada.

Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2024 Aug; Vol. 14 (8), pp. 2235-2248. Date of Electronic Publication: 2024 Jul 30.

Measurement properties of the Inclusion Body Myositis Functional Rating Scale.

Autor: Salam S; Department of Neuromuscular Diseases, University College London, London, UK., Symonds T; Clinical Outcomes Solutions Ltd, Folkestone, UK., Doll H; Clinical Outcomes Solutions Ltd, Folkestone, UK., Rousell S; Clinical Outcomes Solutions Ltd, Folkestone, UK., Randall J; Clinical Outcomes Solutions Ltd, Folkestone, UK., Lloyd-Price L; Clinical Outcomes Solutions Ltd, Folkestone, UK., Hudgens S; Clinical Outcomes Solutions Ltd, Tucson, Arizona, USA., Guldberg C; Orphazyme Aps, Copenhagen, Denmark., Herbelin L; Department of Neurology, University of Missouri, Columbia, Missouri, USA., Barohn RJ; Department of Neurology, University of Missouri, Columbia, Missouri, USA., Hanna MG; Department of Neuromuscular Diseases, University College London, London, UK., Dimachkie MM; Department of Neurology, University of Kansas City Medical Center, Kansas City, Missouri, USA., Machado PM; Department of Neuromuscular Diseases, University College London, London, UK p.machado@ucl.ac.uk.; NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals National Health Service (NHS) Trust, London, UK.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Jul 11. Date of Electronic Publication: 2024 Jul 11.

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

Autor: Hudgens S; Clinical Outcomes Solutions, Tucson, AZ, USA. Electronic address: stacie.hudgens@clinoutsolutions.com., Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Floden L; Clinical Outcomes Solutions, Tucson, AZ, USA., Harrison CN; Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, England, UK., Palmer J; Department of Hematology, Mayo Clinic, Phoenix, AZ, USA., Gupta V; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada., McLornan D; Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, England, UK., McMullin MF; School of Medicine, Dentistry and Biomedical Sciences, Queens University, Belfast City Hospital Trust, Belfast, Northern Ireland, UK., Kiladjian JJ; Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, Paris, France., Foltz L; Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada., Platzbecker U; Department of Hematology, Hemostaseology, Cellular Therapy and Infectiology, Leipzig University Hospital, Leipzig, Germany., Fox ML; Department of Haematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Mead AJ; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, England, UK., Ross DM; College of Medicine and Public Health, Flinders Medical Centre and University, Adelaide, SA, Australia., Oh ST; Division of Hematology, Washington University School of Medicine, St. Louis, MO, USA., Perkins AA; Department of Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia., Leahy MF; Department of Haematology, University of Western Australia, Perth, WA, Australia., Deheshi S; Sierra Oncology, a GSK company, San Mateo, CA, USA., Donahue R; Sierra Oncology, a GSK company, San Mateo, CA, USA., Klencke BJ; Sierra Oncology, a GSK company, San Mateo, CA, USA., Mesa RA; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 May; Vol. 27 (5), pp. 607-613. Date of Electronic Publication: 2024 Feb 02.

[Special issue PRO] A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes.

Autor: Floden L; Quantitative Sciences, Clinical Outcomes Solutions LLC, Tucson, USA., DeRosa M; Quantitative Sciences, Clinical Outcomes Solutions LLC, Tucson, USA., Roydhouse J; Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia., Beaumont JL; Quantitative Sciences, Clinical Outcomes Solutions LLC, Tucson, USA., Hudgens S; Quantitative Sciences, Clinical Outcomes Solutions LLC, Tucson, USA.

Publikováno v: Journal of biopharmaceutical statistics [J Biopharm Stat] 2024 Apr 30, pp. 1-15. Date of Electronic Publication: 2024 Apr 30.

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab

Autor: Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A

Publikováno v: Patient Preference and Adherence, Vol Volume 10, Pp 1767-1776 (2016)

Christina Theodore-Oklota,1 Louise Humphrey,2 Christof Wiesner,1 Gabriel Schnetzler,3 Stacie Hudgens,4 Alicyn Campbell1 1Genentech, South San Francisco, CA, USA; 2Adelphi Values, Macclesfield, Cheshire, UK; 3F. Hoffmann La-Roche Ltd, Basel, Switzerla

Externí odkaz: https://doaj.org/article/3496b96add104858a88b17e1aebfd45c